Table 2 Univariable Cox regression
Parameter | Progression-free survival | Overall survival | ||
|---|---|---|---|---|
Hazard ratio (95% CI) | p-value | Hazard ratio (95% CI) | p-value | |
cfDNA fragment size B1 (continuous) | 0.913 (0.865–0.962) | 0.001 | 0.897 (0.848–0.949) | < 0.001 |
cfDNA fragment size B1 (> 167 bp vs ≤ 167 bp) | 0.409 (0.225–0.744) | 0.003 | 0.394 (0.220–706) | 0.002 |
cfDNA level B1 (continuous) | 1.002 (1.001–1.003) | 0.001 | 1.002 (1.001–1.003) | 0.001 |
cfDNA level B1 (> median vs ≤ median) | 3.773 (2.009–7.084) | < 0.001 | 2.418 (1.350–4.329) | 0.003 |
Combination cfDNA fragment size and cfDNA levels | < 0.001 | 0.002 | ||
0 markersa | Reference | Reference | ||
1 marker | 2.825 (1.275–6.258) | 2.032 (0.943–4.379) | ||
2 markers | 4.476 (2.139–9.364) | 3.326 (1.695–6.526) | ||
CA 19-9 (< 37U/mL vs ≥ 37U/mL) | 0.665 (0.319–1.385) | 0.276 | 0.854 (0.412–1.771) | 0.672 |
cfDNA fragment size B2 (continuous) | 0.935 (0.860–1.017) | 0.116 | 0.981 (0.899–1.070) | 0.662 |
cfDNA fragment size B2 (> 167 bp vs ≤ 167 bp) | 0.498 (0.245–1.011) | 0.054 | 0.841 (0.413–1.715) | 0.635 |
cfDNA levels B2 (continuous) | 1.061 (1.028–1.095) | < 0.001 | 1.062 (1.026–1.099) | 0.001 |
cfDNA levels B2 (> median vs ≤ median) | 1.626 (0.786–3.365) | 0.190 | 1.412 (0.664–3.002) | 0.371 |
Age at diagnosis | 1.003 (0.973–1.035) | 0.833 | 0.990 (0.957–1.023) | 0.539 |
Sex (male vs female) | 1.194 (0.688–2.070) | 0.529 | 1.194 (0.671–2.124) | 0.546 |
Center (SUH vs HUH) | 2.176 (1.153–4.105) | 0.016 | 2.213 (1.130–4.337) | 0.021 |
Tumor size (mm) | 1.030 (1.012–1.049) | 0.001 | 1.021 (1.001–1.041) | 0.042 |
Tumor location | 0.075 | 0.075 | ||
Pancreas head | Reference | Reference | ||
Pancreas body | 0.616 (0.182–2.088) | 0.657 (0.197–2.195) | ||
Pancreas tail | 2.314 (1.165–4.596) | 2.239 (1.125–4.458) | ||
Multiple | 1.135 (0.531–2.425) | 1.581 (0.732–3.434) | ||
T-stage | 0.342 | 0.350 | ||
T2 | Reference | Reference | ||
T3 | 1.116 (0.471–2.645) | 0.922 (0.367–2.318) | ||
T4 | 0.664 (0.314–1.403) | 0.603 (0.281–1.294) | ||
Clinical stage (Stage IV vs Stage III) | 2.147 (0.836–5.515) | 0.112 | 1.829 (0.715–4.678) | 0.207 |
Metastatic location | 0.457 | 0.735 | ||
Liver | Reference | Reference | ||
Lung | 0.382 (0.113–1.288) | 0.590 (0.195–1.781) | ||
Multiple | 0.726 (0.271–1.944) | 0.767 (0.262–2.240) | ||
Other | 0.841 (0.439–1.610) | 0.740 (0.366–1.496) | ||
N-stage (N1 vs N0) | 1.745 (0.760–4.006) | 0.189 | 1.566 (0.703–3.488) | 0.273 |
ECOG performance status | 0.003 | < 0.001 | ||
0 | Reference | Reference | ||
1 | 1.656 (0.809–3.389) | 1.634 (0.782–3.415) | ||
2 | 5.057 (1.932–13.235) | 6.810 (2.537–18.277) | ||
First-line treatment | < 0.001 | < 0.001 | ||
FOLFIRINOX | Reference | Reference | ||
Gemcitabine | 14.760 (4.874–44.697) | 15.099 (4.951–46.047) | ||
Nab-Pac + gemcitabine | 2.796 (1.481–5.280) | 3.201 (1.665–6.155) | ||
Second-line treatment (yes vs no) | 0.822 (0.453–1.490) | 0.519 | 0.494 (0.255–0.955) | 0.036 |
Prior anti-cancer surgery (yes vs no) | 0.601 (0.287–1.260) | 0.178 | 0.722 (0.324–1.612) | 0.427 |